指南与共识神经免疫

血清神经丝轻链作为进展型多发性硬化生物标志物

Serum neurofilament light as a biomarker in progressive multiple sclerosis.
指南 / 共识 · Neurology · 2020-07-16

国际进展型MS联盟于2019年1月召集专家小组,评估血清/血浆神经丝轻链(NfL)在复发型和进展型MS中的数据,提出sNfL与影像和残疾指标相关、可预测疾病进程和治疗反应,但需区分炎症活动与进展,并建立标准化检测流程。

要点

  • sNfL是神经退行性变的可行标志物,可准确、灵敏、可重复检测。
  • sNfL浓度与影像和残疾指标相关,可预测疾病进程和治疗反应。
  • 需区分炎症活动与进展,并建立样本处理和分析标准流程。

核心结论

  • sNfL是进展型MS中可行的神经退行性变标志物,但需标准化检测并区分炎症活动与疾病进展。

研究设计与样本

  • 国际进展型MS联盟于2019年1月召集常设专家小组,审查复发型和进展型MS中血清/血浆NfL数据。

主要发现

  • sNfL浓度与影像和残疾指标相关,可预测未来疾病进程和治疗反应。
  • 活动性炎症(新T2和钆增强病灶)对sNfL贡献大,区分其与进展驱动因素具有挑战性。

临床怎么用

  • sNfL可作为进展型MS的候选生物标志物,但需先建立标准化样本处理和分析流程。

局限性

  • 年龄和合并症对sNfL的影响数据不足,炎症活动与其他疾病过程的相对贡献需更多研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the International Progressive MS Alliance convened a standing expert panel to consider potential tissue fluid biomarkers in MS in general and in progressive MS specifically. The panel focused their attention on neurofilament light chain (NfL) in serum or plasma, examining data from both relapsing and progressive MS. Here, we report the initial conclusions of the panel and its recommendations for further research. Serum NfL (sNfL) is a plausible marker of neurodegeneration that can be measured accurately, sensitively, and reproducibly, but standard procedures for sample processing and analysis should be established. Findings from relapsing and progressive cohorts concur and indicate that sNfL concentrations correlate with imaging and disability measures, predict the future course of the disease, and can predict response to treatment. Importantly, disease activity from active inflammation (i.e., new T2 and gadolinium-enhancing lesions) is a large contributor to sNfL, so teasing apart disease activity from the disease progression that drives insidious disability progression in progressive MS will be challenging. More data are required on the effects of age and comorbidities, as well as the relative contributions of inflammatory activity and other disease processes. The International Progressive MS Alliance is well positioned to advance these initiatives by connecting and supporting relevant stakeholders in progressive MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kapoor R, Smith KE, Allegretta M, et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. 2020. PMID: 32675076. doi:10.1212/WNL.0000000000010346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。